MPM
PDLI

Meritage Portfolio Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Meritage Portfolio Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-275,015
Closed -$2.32M – 225
2013
Q4 		$2.32M Sell
275,015
-1,850
-0.7% -$15.6K 0.29% 161
2013
Q3 		$2.21M Sell
276,865
-1,995
-0.7% -$16K 0.29% 158
2013
Q2 		$2.15M Buy
+278,860
New +$2.17M 0.31% 153

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Advisors Asset Management
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Meritage Portfolio Management's PDLI Position: Q1 2014 in Review

Meritage Portfolio Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2014, closing a stake of 275,015 shares — an estimated $2.32M sold.

Meritage Portfolio Management first reported a position in PDLI in Q2 2013 and held it in 3 quarters. The position peaked at $2.32M in Q4 2013. 233 funds tracked by Wall St. Rank hold PDLI as of Q1 2014.

  • Meritage Portfolio Management reported no remaining PDL BioPharma, Inc. position as of Q1 2014 after selling out during the quarter.
  • Meritage Portfolio Management sold 275,015 PDL BioPharma, Inc. shares in Q1 2014, an estimated $2.32M.
  • Meritage Portfolio Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 3 quarters.
  • Meritage Portfolio Management's PDL BioPharma, Inc. position peaked at $2.32M in Q4 2013.
  • 233 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2014.

Based on Meritage Portfolio Management's 13F filing for Q1 2014, filed 29 Apr 2014.